0001209191-18-049247.txt : 20180904 0001209191-18-049247.hdr.sgml : 20180904 20180904170314 ACCESSION NUMBER: 0001209191-18-049247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180830 FILED AS OF DATE: 20180904 DATE AS OF CHANGE: 20180904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walsh Jeffrey T. CENTRAL INDEX KEY: 0001578251 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 181052971 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-30 0 0001293971 bluebird bio, Inc. BLUE 0001578251 Walsh Jeffrey T. C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 1 Chief Financial and Strategy Officer Common Stock 2018-08-30 4 M 0 8743 2.0864 A 44238 D Common Stock 2018-08-30 4 M 0 4007 5.5004 A 48245 D Common Stock 2018-08-30 4 M 0 7250 24.47 A 55495 D Common Stock 2018-08-30 4 S 0 19022 175.365 D 36473 D Common Stock 2018-08-30 4 S 0 978 176.0273 D 35495 D Stock Option (right to buy) 2.0864 2018-08-30 4 M 0 8743 0.00 D 2021-07-13 Common Stock 8743 0 D Stock Option (right to buy) 5.5004 2018-08-30 4 M 0 4007 0.00 D 2023-01-16 Common Stock 4007 0 D Stock Option (right to buy) 24.47 2018-08-30 4 M 0 7250 0.00 D 2024-03-03 Common Stock 7250 25021 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. The range of prices for the transaction reported on this line was $175.00 to $175.95. The average weighted price was $175.365. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $176.00 to $176.20. The average weighted price was $176.0273. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vested over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013 and April 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014 and April 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years. This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-Fact 2018-09-04